|
|
|
|
Arrivent Biopharma inc (AVBP) |
|
Price: $28.7400
$1.24 
4.509%
|
| Day's High:
| $29.16
| Week Perf:
| 4.85 %
|
| Day's Low: |
$ 27.15 |
30 Day Perf: |
-10.66 % |
| Volume (M): |
226 |
52 Wk High: |
$ 36.37 |
| Volume (M$): |
$ 6,504 |
52 Wk Avg: |
$23.63 |
| Open: |
$27.23 |
52 Wk Low: |
$15.53 |
|
|
| Market Capitalization (Millions $) |
965 |
| Shares
Outstanding (Millions) |
34 |
| Employees |
36 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-60 |
| Cash Flow (TTM) (Millions $) |
132 |
| Capital Exp. (TTM) (Millions $) |
0 |
Arrivent Biopharma Inc
Company Address: 18 Campus Boulevard Suite 100 Newtown Square 19073 PA
Company Phone Number: 277-4836 Stock Exchange / Ticker: NASDAQ AVBP
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Clinical Study
Published Mon, Sep 9 2024 4:05 PM UTC
Title : Promising Phase 1b Data Elevates ArriVent s Firmonertinib as a Leading Candidate for EGFR PACC Mutant NSCLCAt the 2024 World Conference on Lung Cancer, ArriVent BioPharma presented compelling interim data from their global Phase 1b trial, showcasing the efficacy of Firmonertinib a selective EGFR inhibitor designed for patients with EGFR PACC mutant non-small cell lun...
|
| Product Service News
Published Wed, Jun 5 2024 11:00 AM UTC
Overview of ArriVent and Alphamab's Multi-Target ADC CollaborationIn a groundbreaking development within the pharmaceutical industry, ArriVent has recently announced a strategic collaboration with Alphamab. This partnership aims to leverage Alphamab's advanced antibody-drug conjugate (ADC) research and discovery platform in conjunction with ArriVent's global expertise in d...
|
| Per Share |
Current |
| Earnings (TTM) |
-1.96 $ |
| Revenues (TTM) |
-
|
| Cash Flow (TTM) |
3.94 $ |
| Cash |
8.42 $
|
| Book Value |
8.26 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.96 $
|
| Revenues (TTM) |
- |
| Cash Flow (TTM) |
3.94 $ |
| Cash |
8.42 $
|
| Book Value |
8.26 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
2.69% 